TY - CHAP
T1 - Identification of a novel gene on 10q22.1 causing autosomal dominant retinitis pigmentosa (adRP)
AU - Daiger, Stephen P.
AU - Sullivan, Lori S.
AU - Bowne, Sara J.
AU - Koboldt, Daniel C.
AU - Blanton, Susan H.
AU - Wheaton, Dianna K.
AU - Avery, Cheryl E.
AU - Cadena, Elizabeth D.
AU - Koenekoop, Robert K.
AU - Fulton, Robert S.
AU - Wilson, Richard K.
AU - Weinstock, George M.
AU - Lewis, Richard A.
AU - Birch, David G.
N1 - Funding Information:
We dedicate this report to the memory of Dr. Mary Kay Pelias who worked closely with the Louisiana families throughout her career. This work was supported by NIH grant EY007142, by grant HG003079 from the NHGRI, by a Wynn-Gund TRAP Award, and by the Foundation Fighting Blindness.
Publisher Copyright:
© Springer International Publishing Switzerland 2016.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Whole-genome linkage mapping identified a region on chromosome 10q21.3-q22.1 with a maximum LOD score of 3.0 at 0 % recombination in a sixgeneration family with autosomal dominant retinitis pigmentosa (adRP). All known adRP genes and X-linked RP genes were excluded in the family by a combination of methods. Whole-exome next-generation sequencing revealed a missense mutation in hexokinase 1, HK1 c.2539G > A, p.Glu847Lys, tracking with disease in all affected family members. One severely-affected male is homozygous for this region by linkage analysis and has two copies of the mutation. No other potential mutations were detected in the linkage region nor were any candidates identified elsewhere in the genome. Subsequent testing detected the same mutation in four additional, unrelated adRP families, for a total of five mutations in 404 probands tested (1.2 %). Of the five families, three are from the Acadian population in Louisiana, one is French Canadian and one is Sicilian. Haplotype analysis of the affected chromosome in each family and the homozygous individual revealed a rare, shared haplotype of 450 kb, suggesting an ancient founder mutation. HK1 is a widelyexpressed gene, with multiple, abundant retinal transcripts, coding for hexokinase 1. Hexokinase catalyzes phosphorylation of glucose to glusose-6-phospate, the first step in glycolysis. The Glu847Lys mutation is in a highly-conserved site, outside of the active site or known functional sites.
AB - Whole-genome linkage mapping identified a region on chromosome 10q21.3-q22.1 with a maximum LOD score of 3.0 at 0 % recombination in a sixgeneration family with autosomal dominant retinitis pigmentosa (adRP). All known adRP genes and X-linked RP genes were excluded in the family by a combination of methods. Whole-exome next-generation sequencing revealed a missense mutation in hexokinase 1, HK1 c.2539G > A, p.Glu847Lys, tracking with disease in all affected family members. One severely-affected male is homozygous for this region by linkage analysis and has two copies of the mutation. No other potential mutations were detected in the linkage region nor were any candidates identified elsewhere in the genome. Subsequent testing detected the same mutation in four additional, unrelated adRP families, for a total of five mutations in 404 probands tested (1.2 %). Of the five families, three are from the Acadian population in Louisiana, one is French Canadian and one is Sicilian. Haplotype analysis of the affected chromosome in each family and the homozygous individual revealed a rare, shared haplotype of 450 kb, suggesting an ancient founder mutation. HK1 is a widelyexpressed gene, with multiple, abundant retinal transcripts, coding for hexokinase 1. Hexokinase catalyzes phosphorylation of glucose to glusose-6-phospate, the first step in glycolysis. The Glu847Lys mutation is in a highly-conserved site, outside of the active site or known functional sites.
KW - Autosomal dominant retinitis pigmentosa
KW - Founder effect
KW - Hexokinase
KW - Linkage mapping
KW - Next-generation sequencing
KW - Retinitis pigmentosa
UR - http://www.scopus.com/inward/record.url?scp=84943279726&partnerID=8YFLogxK
U2 - 10.1007/978-3-319-17121-0_26
DO - 10.1007/978-3-319-17121-0_26
M3 - Chapter
C2 - 26427411
AN - SCOPUS:84943279726
T3 - Advances in Experimental Medicine and Biology
SP - 193
EP - 200
BT - Advances in Experimental Medicine and Biology
PB - Springer New York LLC
ER -